Inivata is a Leader

in Liquid Biopsy
 
 
Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

Our US Medicare-reimbursed lead product InVisionFirst-Lung is already transforming the lives of advanced NSCLC patients

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

Our Technology

Contact Us

Latest News and Events

Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study

Inivata to provide ctDNA liquid biopsy using its InVisionFirst®-Lung test to analyze resistance in patients treated with lorlatinib ... Read More

Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)

Daniel Morgensztern, Emma Green, Jennifer C. King, Alicia Sable-Hunt, Richard Erwin, Amy Moore, Tony Addario, Clive Morris, Ramaswamy ... Read More

PMWC

PMWC

Event expiration date display - 21 - 24 JAN 2020

Location: Santa Clara Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

We are looking forward to attending @PMWCintl #PMWC20 next week. @antonynewton001, VP BD and Dr Tadd Lazarus, CMO will be attending. Don’t miss our session on Friday 24, 11am (Track 6) - The critical importance of sensitivity in #Liquidbiopsy. Join us!

Cancer is too personal for @jillfeldman4, and research advances have kept her and others alive who have #EGRF disease. Finding your people online who mutually educate/commiserate is so important. #lung20 #lcsm

We got a primer on the development of vaccines for lung cancer this morning from Edward Garon. Personalized vaccines in intriguing.#lung20 #lcsm